AS PRFoods Resolutions of the Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailAS PRFoods resolutions of the Shareholders adopted by the General Meeting of Shareholders of AS PRFoods on 29.12.2023 without calling a meeting
The general meeting of shareholders (the Meeting) of AS PRFoods (the Company) was held without convening a meeting in accordance with § 2991 of the Commercial Code. The voting took place via submitting the voting ballots during the period from 11.12.2023 to 29.12.2023. According to the Commercial Code, in the event of non-voting, the shareholder is deemed to have voted against the resolution.
Following the submission of the voting ballots, the Meeting adopted the following resolutions:
1. Approval of 01.07.2022 – 30.06.2023 annual report
To approve the 01.07.2022 – 30.06.2023 annual report of AS PRFoods.
Voting results:
| Votes | Number of Votes | Proportion to total votes (%) |
| In favour | 24,390,085 | 63.0514% |
| Against (did not vote) | 14,292,775 | 36.9486% |
| Impartial | 0 | 0% |
| Total | 38,682,860 | 100% |
2. Distribution of profit
The profit for the period 01.07.2022 - 30.06.2023 was EUR 331,000. To use the profit to cover the losses of previous periods. No dividend to be paid out of the profit.
Voting results:
| Votes | Number of Votes | Proportion to total votes (%) |
| In favour | 24,390,085 | 63.0514% |
| Against (did not vote) | 14,292,775 | 36.9486% |
| Impartial | 0 | 0% |
| Total | 38,682,860 | 100% |
The resolutions were adopted in accordance with the stipulations of the law and Company’s articles of association.
Indrek Kasela
AS PRFoods
Management board member
T: +372 452 1470
[email protected]
www.prfoods.ee
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
- Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
